| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies M Egger, M May, G Chêne, AN Phillips, B Ledergerber, F Dabis, ... The Lancet 360 (9327), 119-129, 2002 | 1846 | 2002 |
| Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global … H Wang, M Naghavi, C Allen, RM Barber, ZA Bhutta, A Carter, DC Casey, ... The lancet 388 (10053), 1459-1544, 2016 | 1730 | 2016 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. TCC Antiretroviral Lancet 372 (9635), 293, 2008 | 1553 | 2008 |
| Effect of early versus deferred antiretroviral therapy for HIV on survival MM Kitahata, SJ Gange, AG Abraham, B Merriman, MS Saag, AC Justice, ... New England Journal of Medicine 360 (18), 1815-1826, 2009 | 1415 | 2009 |
| Improved survival among HIV-infected individuals following initiation of antiretroviral therapy RS Hogg, KV Heath, B Yip, KJP Craib, MV O'shaughnessy, MT Schechter, ... Jama 279 (6), 450-454, 1998 | 971 | 1998 |
| Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies When To Start Consortium The Lancet 373 (9672), 1352-1363, 2009 | 930 | 2009 |
| Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada H Samji, A Cescon, RS Hogg, SP Modur, KN Althoff, K Buchacz, ... PloS one 8 (12), 2013 | 916 | 2013 |
| Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy RS Hogg, B Yip, KJ Chan, E Wood, KJP Craib, MV O'Shaughnessy, ... Jama 286 (20), 2568-2577, 2001 | 910 | 2001 |
| Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study JSG Montaner, VD Lima, R Barrios, B Yip, E Wood, T Kerr, K Shannon, ... The Lancet 376 (9740), 532-539, 2010 | 811 | 2010 |
| The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic JSG Montaner, R Hogg, E Wood, T Kerr, M Tyndall, AR Levy, PR Harrigan The Lancet 368 (9534), 531-536, 2006 | 596 | 2006 |
| Causes of death in HIV-1–infected patients treated with antiretroviral therapy, 1996–2006: Collaborative analysis of 13 HIV cohort studies ATC Collaboration Clinical infectious diseases: an official publication of the Infectious …, 2010 | 541 | 2010 |
| Barriers to use of free antiretroviral therapy in injection drug users SA Strathdee, A Palepu, PGA Cornelisse, B Yip, MV O'Shaughnessy, ... Jama 280 (6), 547-549, 1998 | 517 | 1998 |
| Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy PR Harrigan, RS Hogg, WWY Dong, B Yip, B Wynhoven, J Woodward, ... The Journal of infectious diseases 191 (3), 339-347, 2005 | 475 | 2005 |
| Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up RS Hogg, K Heath, D Bangsberg, B Yip, N Press, MV O'Shaughnessy, ... Aids 16 (7), 1051-1058, 2002 | 454 | 2002 |
| Decline in deaths from AIDS due to new antiretrovirals RS Hogg, MV O'Shaughnessy, N Gataric, B Yip, K Craib, MT Schechter, ... The Lancet 349 (9061), 1294, 1997 | 437 | 1997 |
| Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350× 109 cells/L E Wood, RS Hogg, B Yip, PR Harrigan, MV O'Shaughnessy, ... Annals of internal medicine 139 (10), 810-816, 2003 | 430 | 2003 |
| Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda EJ Mills, C Bakanda, J Birungi, K Chan, N Ford, CL Cooper, JB Nachega, ... Annals of internal medicine 155 (4), 209-216, 2011 | 424 | 2011 |
| Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens RS Hogg, B Yip, C Kully, KJP Craib, MV O'Shaughnessy, MT Schechter, ... Cmaj 160 (5), 659-665, 1999 | 383 | 1999 |
| Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies Antiretroviral Therapy (ART) Cohort Collaboration AIDS (London, England) 21 (9), 1185, 2007 | 382 | 2007 |
| Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study E Wood, T Kerr, BDL Marshall, K Li, R Zhang, RS Hogg, PR Harrigan, ... Bmj 338, b1649, 2009 | 358 | 2009 |
Martin T. SchechterProfessor of Population and Public Health, University of British ColumbiaVerified email at ubc.ca
